SynthesisAllergy2014
Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure.
Synthesis in Allergy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 67 citations in OpenAlex.
- Subcutaneous Allergen Immunotherapy in Adults Allergic to House Dust Mites: A Phase 3 Randomized Controlled Trial.Allergy · 2025Trial
- Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019Trial
- Trial
- Trial
- Symptom probability increases at low pollen exposure in adolescents with allergic rhinitis findings from the GINIplus and LISA birth cohorts.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- Prospective Evaluation of Symptom Burden and Medication Use in Seasonal Allergic Rhinitis/Rhinoconjunctivitis Patients Considering Allergen-Specific Immunotherapy.Journal of clinical medicine · 2026Article
- Effect of initiation treatment timing on efficacy ofThe World Allergy Organization journal · 2026Article
- Efficacy ofJournal of asthma and allergy · 2026Article
- Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform: a retrospective longitudinal cohort study.Frontiers in allergy · 2026Article
- A Modern Approach to Clinical Outcome Assessment in Allergy Management: Advantages of Allergen Exposure Chambers.Journal of clinical medicine · 2024Review
- Pollen effects in a changing climate: Ragweed pollen exposure and sleepiness in immunotherapy patients of a Southeastern Michigan allergy clinic.International journal of biometeorology · 2024Article
- Clinical relevance of pre- and coseasonal sublingual immunotherapy with a 300 index of reactivity 5-grass SLIT tablet in allergic rhinoconjunctivitis.Clinical and translational allergy · 2023Article
- Clinical response to varying pollen exposure in allergic rhinitis in children in The Netherlands.BMC pediatrics · 2023Article
- Allergen challenge tests in allergen immunotherapy: State of the art.Allergologie select · 2023Review
- Dogmas, challenges, and promises in phase III allergen immunotherapy studies.The World Allergy Organization journal · 2021Review
- Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy.Clinical and translational allergy · 2020Review
- Review
- Positive and negative AIT trials: What makes the difference?Allergo journal international · 2018Review
- Pollen and spore monitoring in the world.Clinical and translational allergy · 2018Article
- Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles.Current allergy and asthma reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundThe objective was to evaluate the association between grass pollen exposure, allergy symptoms and impact on measured treatment effect after grass sublingual immunotherapy (SLIT)-tablet treatment.
methodsThe association between grass pollen counts and total combined rhinoconjunctivitis symptom and medication score (TCS) was based on a post hoc analysis of data collected over six trials and seven grass pollen seasons across North America and Europe, including 2363 subjects treated with grass SLIT-tablet or placebo. Daily pollen counts were obtained from centralized pollen databases. The effect of treatment on the relationship between the TCS and pollen counts was investigated, and the relative difference between grass SLIT-tablet and placebo as a function of average grass pollen counts was modelled by linear regression.
resultsThe magnitude of treatment effect based on TCS was greater with higher pollen exposure (P < 0.001). The relative treatment effect in terms of TCS for each trial was correlated with the average grass pollen exposure during the first period of the season, with predicted reduction in TCS = 12% + 0.35% × pollen count (slope significantly different from 0, P = 0.003; R(2) = 0.66). Corresponding correlations to the entire grass pollen season and to the peak season were equally good, whereas there was a poor correlation between difference in measured efficacy and pollen exposure during the last part of the season.
conclusionsIn seasonal allergy trials with grass SLIT-tablet, the observed treatment effect is highly dependent on pollen exposure with the magnitude being greater with higher pollen exposure. This is an important relationship to consider when interpreting individual clinical trial results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.